Lakhmir S. Chawla, MD | Chief Medical Officer

Dr. Chawla joined La Jolla as Chief Medical Officer, effective July 1, 2015. Previously, Dr. Chawla was a Professor of Medicine at the George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was also the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. Data from the ATHOS trial was published in the medical journal Critical Care during 2014 and demonstrated the utility of angiotensin II in patients with severe shock. These data were also used in support of the initiation of La Jolla’s ATHOS 3 trial, a Phase 3 clinical trial of LJPC-501, La Jolla’s proprietary formulation of angiotensin II, for the treatment of catecholamine-resistant hypotension, which was initiated in March 2015. Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI) and was an active investigator in the fields of inflammation and AKI, AKI biomarkers, AKI risk prediction, chronic kidney disease caused by AKI and AKI therapeutics. In addition, Dr. Chawla was an active investigator in shock, inflammation and extracorporeal therapies, including: continuous renal replacement therapy, dialysis and albumin dialysis. Dr. Chawla is also the author of over 100 peer-reviewed publications and was previously an Associate Editor for the Clinical Journal of the American Society of Nephrology.

Dennis M. Mulroy | Chief Financial Officer

Mr. Mulroy has been the Chief Financial Officer of La Jolla since April 2015. Prior to joining La Jolla, Mr. Mulroy served as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc., a publicly traded biotechnology company, since 2005. Prior to joining Taxus Cardium, Mr. Mulroy served as Chief Financial Officer of Molecular Imaging, Inc. and SeraCare Life Sciences, Inc., and held financial management positions of increasing responsibility at several other companies. Mr. Mulroy began his career as a Certified Public Accountant with Ernst & Young LLP in San Diego and holds a degree in Business Administration, with an emphasis in Accounting, from the University of San Diego.

James M. Rolke | Chief Scientific Officer

Mr. Rolke has been the Chief Scientifc Officer at La Jolla since January 2017. Prior to that Mr. Rolke served as Vice President of Research & Development and Senior Director of Research & Development at La Jolla since January 2012. Mr. Rolke has over 25 years of experience in the biotechnology industry. Prior to joining La Jolla, Mr. Rolke held several key positions at biotechnology companies, including Chief Technology Officer at Pluromed, Inc. (acquired by Sanofi), Director of Operations at Prospect Therapeutics, Inc., Associate Director of Pharmaceutical Development at Mersana Therapeutics, Inc., Manager of Process Development at GlycoGenesys, Inc., Principal Scientist at Surgical Sealants, Inc., Scientist at GelTex, Inc., and Associate Scientist at Alpha-Beta Technology, Inc. Mr. Rolke received his B.S. in chemistry from Keene State College.

Darryl Wellinghoff | Chief Commercial Officer

Mr. Wellinghoff brings 22 years of industry experience in building and leading teams through the launch of multiple products that stretch across all areas of healthcare. He started in the industry at Bristol-Myers Squibb where he launched products in neuroscience, infectious disease and metabolics quickly rising to top performance and taking on roles of greater responsibility. After several years he was recruited to The Medicines Company in 2001 where he successfully launched Angiomax throughout the South Florida hospital market. Mr. Wellinghoff’s career grew rapidly at The Medicines Company where he would spend the next 15 years building and leading teams through the launch of multiple hospital-based products in the U.S. hospital market. He was an integral part of taking Angiomax from a product that was forecasted to generate $120m in peak revenue to a $635m product by the time he left in 2016. For the past 3 years he led the build-out of a post-acute care model that disrupted the nursing home space, bringing a physician led short-stay model of care that delivered measurable value to patients, payers, and hospital providers. Mr. Wellinghoff brings over 2 decades of experience to La Jolla in launching products into the acute care space and working across multiple patient pathways that extends from pre-hospital, to acute episodes managed in the hospital and finally in the post-acute setting.